While our findings demonstrate the therapeutic potential of DAPK1 reactivation in HGSOC, several limitations should be acknowledged: 1—Our in vitro and 3D organoid models, though informative, may not fully recapitulate the tumor microenvironment or immune interactions observed in vivo. This evidence concerns the gene DAPK1 and neoplasm.